EVAX News and Press, Evaxion Biotech A/S From 07/11/25

Evaxion and the European Investment Bank (EIB) have finalized a debt settlement agreement of €3.5 million out of Evaxion’s €7 million loan with EIB, to be used for EIB to purchase €3.5 million worth of ordinary Evaxion warrants EIB will purchase the warrants at...

Chief Executive Officer (CEO) Christian Kanstrup steps down Chief Scientific Officer Birgitte Rønø appointed interim CEO and search for new CEO has commenced Thomas Schmidt appointed permanent Chief Financial Officer COPENHAGEN, Denmark, July 1, 2025 - Evaxion ...

Initial computational analysis demonstrated that Evaxion’s AI-Immunology™ platform can identify novel vaccine targets to combat Group A Streptococcus (GAS) New vaccine program is added to Evaxion’s pipeline under the name EVX-B4 Urgent need for...

Evaxion awarded a grant from the Gates Foundation Grant funds research aimed at ultimately eradicating polio, a highly infectious viral disease Evaxion will apply its leading AI-Immunology™ platform to identify and combine various antigens to combat the virus and develop de...

2025-05-28 04:39:31 ET More on Evaxion Biotech ADS Evaxion A/S 2025 Q1 - Results - Earnings Call Presentation Evaxion A/S (EVAX) Q1 2025 Earnings Call Transcript Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025 Evaxion Biotech ADS GAAP EPS of...

2025-05-27 10:43:23 ET Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call May 27, 2025, 08:30 PM ET Company Participants Christian Kanstrup - CEO Birgitte Rono - Chief Scientific Officer Thomas Schmidt - CFO Conference Call Participants...

2025-05-27 07:33:31 ET More on Evaxion Biotech ADS Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025 Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript Evaxion Biotech A/S 2024 Q4 - Results - Earnings Call Presentation Evaxion Biotech...

COPENHAGEN, Denmark, May 27, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces first quarter 2025 financial results. Business highlights (sin...

Okta Inc. (OKTA) is expected to report $0.24 for Q1 2026 Kidpik Corp. (PIKM) is expected to report for quarter end 2025-03-31 Hillcrest Energy Technologies Ltd (HLRTF) is expected to report for quarter end 2025-03-31 Croda International plc ADR (COIHY) is expected to report for Q1 202...

Evaxion A/S (EVAX) is expected to report $-0.65 for Q1 2025